I see that DRL is claiming a 36% total market share for...

I see that DRL is claiming a 36% total market share for November; up from 33% in August. Perhaps inconsistent with last ACL update, which indicated a 30% market share for 3 months ending September 30. And, as we know, increasing market share doesn't necessarily translate to increasing profits.

But, hopefully a positive trend, that combined with process improvements could/should see an improved ACL return for last quarter. At least back to the $3 million received for June qtr; and hopefully more.

I realise that oncology is the big opportunity for ACL going forward. But having a decent revenue stream from fonda is sure a bonus for a biotech.